Aspira Pathlab & Diagnostics shareholding pattern

ASPIRA

66.88

4.06 (6.46%)
Last updated on 6 Feb, 2026 | 14:50 IST
alert_iconwatchlist_icon
BUYSELL

alert_iconThe current prices are delayed, login to your account for live prices

Aspira Pathlab & Diagnostics Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

18.39%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

0%

Domestic Institutional Investors

0%

Retail

81.61%

Others

0%

Total Promoters
MAR '25
18.39%
JUN '25
18.39%
SEP '25
18.39%
DEC '25
18.39%

Summary

For Year 2025-26, Aspira Pathlab & Diagnostics reports the following shareholding: Total Promoters at 18.39%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 81.61%. This breakdown provides a quick snapshot of ownership distribution for Aspira Pathlab & Diagnostics in 2025-26.

Aspira Pathlab & Diagnostics FAQs

As of 02-2026, the promoter shareholding in Aspira Pathlab & Diagnostics stands at 18.39% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Aspira Pathlab & Diagnostics is 0% and 0% respectively.

The retail shareholding of the Aspira Pathlab & Diagnostics is 81.61%.

Changes in shareholding patterns of Aspira Pathlab & Diagnostics can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Aspira Pathlab & Diagnostics are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.